Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
The IPA news archive on Stock Titan covers ImmunoPrecise Antibodies Ltd. during its evolution into a bio-native AI and biotherapeutics platform business. Company press releases and related coverage describe how IPA operated at the intersection of TechBio and next-generation drug discovery, combining its LENSai™ platform and HYFT® multi-omics technology with wet-lab capabilities in biologics discovery, engineering, and characterization.
Readers can review news items detailing IPA’s financial results, including discussions of revenue trends, margins, and segment performance, as well as updates on strategic priorities such as focusing on AI-based product development. Coverage also includes corporate developments like the divestiture of ImmunoPrecise Antibodies (Europe) B.V. to AVS Bio, which the company framed as part of a strategic refinement to streamline operations and concentrate resources on its scientific platforms and data-driven discovery technologies.
Scientific and platform-related announcements form another key part of the IPA news flow. These include updates on the LENSai/HYFT platform’s capabilities in areas such as in silico epitope mapping, universal dengue vaccine candidate discovery, AI-designed GLP-1 peptides, and immunogenicity screening aimed at predicting anti-drug-antibody risk. The news stream also reflects corporate milestones like conference participation, advisory board appointments, and the company’s rebranding under the MindWalk name with a Nasdaq ticker change from IPA to HYFT.
For investors, researchers, and industry observers, this page serves as a historical record of ImmunoPrecise Antibodies’ public communications while it traded under the IPA symbol, including its transition toward the MindWalk brand and associated AI-native discovery platform.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) and Pierre Fabre have announced a multi-year research collaboration aimed at developing therapeutic antibodies for up to nine oncology targets. This strategic partnership combines IPA's advanced antibody technologies with Pierre Fabre's expertise in immuno-oncology, enhancing Talem Therapeutics' portfolio. The collaboration includes joint ownership of developed antibodies, with options for licensing, and potential future payments for Talem. Both companies aim to address critical medical needs in cancer treatment.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported a 22% increase in first quarter fiscal 2022 revenues, totaling
ImmunoPrecise Antibodies Ltd. (IPA) has received a three-year approval for the "Crédit d'Impôt Recherche" (CIR) from the French Ministry of Higher Education and Research for its Oss facility in the Netherlands. This initiative offers R&D tax credits to eligible French companies engaging with IPA Europe. The CIR allows for a 30% credit on R&D expenses up to €100 million and 20% for eligible innovation expenses for SMEs up to €400,000. This accreditation enhances IPA’s appeal in Europe as it provides tax relief to French partners for R&D activities.
ImmunoPrecise Antibodies Ltd. (IPA) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 13-15, 2021. CEO Jennifer Bath will present the company's business overview and engage in one-on-one meetings with registered investors. The virtual conference serves as a platform for corporate finance and strategic advisory, with H.C. Wainwright being ranked the #1 Placement Agent since 1998. ImmunoPrecise aims to revolutionize antibody discovery through a comprehensive suite of services.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 13-15, 2021. CEO Jennifer Bath will present an overview of the company's activities and engage in one-on-one meetings with institutional investors. The event will be held virtually, and interested investors can register online to attend the presentation on September 10 at 6:00 PM (EDT). ImmunoPrecise aims to revolutionize antibody discovery through innovative technology and comprehensive services.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host an earnings conference call on September 9, 2021, at 4:30 p.m. ET to discuss its Q1 fiscal year 2022 financial results and business highlights. The call follows a press release of the financial results issued prior to the meeting. Investors can submit questions to the company’s investor relations. The call will be accessible via webcast and phone, reinforcing the company's commitment to investor communication and transparency.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced the promotion of Dr. Barry Duplantis to VP of Client Relations and the appointment of Ms. Carla Dahl as VP of Marketing. Dr. Duplantis, with extensive experience in therapeutic antibody campaigns, aims to lead the client relations team and enhance the company's sales lifecycle. Ms. Dahl, bringing over 25 years of experience in marketing, will focus on brand amplification and targeted campaigns to drive revenue. Dr. Jennifer Bath, CEO, expressed confidence in their potential to accelerate the company's growth in North America, Asia, and Europe.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported fiscal 2021 results, achieving revenues of $17.9 million, a 27% increase from the previous year. The company's net loss rose to $7.3 million from $5 million in 2020, with increased research and development costs totaling $2 million. Adjusted EBITDA significantly improved to $2.3 million compared to $52,000 in 2020. Cash reserves as of April 30, 2021, were $41.8 million. The company remains focused on expanding its global reach and developing novel therapeutic antibodies.
ImmunoPrecise Antibodies Ltd. (IPA) announced promising results for its TATX-03 PolyTope™ Therapy, a monoclonal antibody cocktail targeting SARS-CoV-2. Recent assays show strong pseudovirus neutralization against the Delta variant (B.1.617.2). The company highlighted the importance of developing therapies resistant to viral mutation. TATX-03 has previously shown efficacy in reducing viral loads in hamster models and in vitro against variants Alpha, Beta, and Gamma. IPA emphasizes multi-antibody cocktails as a strategy for sustained treatment amid evolving variants.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) will host a conference call on July 28, 2021, at 4:30 p.m. ET to discuss its fiscal year 2021 financial results and business highlights. The results will be released prior to the call. During the conference, management will provide insights and answer investor questions submitted in advance. Participants can dial in or access the live webcast on the company’s investor section of their website.
FAQ
What is the current stock price of Immunoprecise (IPA)?
What is the market cap of Immunoprecise (IPA)?
